Last reviewed · How we verify
Kalinox
Kalinox is a Small molecule drug developed by Weprom. It is currently in Phase 2 development. Also known as: Control.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Kalinox |
|---|---|
| Also known as | Control |
| Sponsor | Weprom |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy on Anxiety of the Digital Music Application Versus Equimolar Mixture of Oxygen and Nitrous Oxide in Patients Receiving CT-guided Lumbar Infiltration (NA)
- Brain Reactivity to Nitrous Oxyde in Depression : an MRI and Ultrasound Study (PROTOBRAIN Pilote) (NA)
- Contribution of Hypnosis to Anxiety and Pain in Brachytherapy Patients (PHASE2)
- Study of the Efficacy of Kalinox® 170 Bar in Adult Oncology (PHASE4)
- Use of 50% Nitrous Oxide / 50% Oxygen Premix in Primary Care Dental Centers (PHASE3)
- Hyperalgesia and Pain (PHASE1)
- Use of 50% Nitrous Oxide / 50% Oxygen Premix During Liver Biopsy of Focal Lesion (PHASE4)
- Nitrous Oxide for Analgesia During Nasogastric Tube Placement in Young Children (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kalinox CI brief — competitive landscape report
- Kalinox updates RSS · CI watch RSS
- Weprom portfolio CI
Frequently asked questions about Kalinox
What is Kalinox?
Who makes Kalinox?
Is Kalinox also known as anything else?
What development phase is Kalinox in?
Related
- Manufacturer: Weprom — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Control
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing